Good morning … D.C. readers — On Tuesday, join Axios' Mike Allen in kicking off the Axios360 Hometown Tour. He'll be discussing how trade and Washington's economic policies are impacting communities with Agriculture Secretary Sonny Perdue, House Agriculture Chair Mike Conaway, former U.S. Trade Representative Ron Kirk and Chattanooga Mayor Andy Berke. RSVP here.
Mike's tour continues this summer and fall with stops in Savannah, Denver and Los Angeles. Stay in the loop.
Let’s jump into the debate Democrats are going to be having for at least the next two years: What, exactly, constitutes “Medicare for All”?
Why it matters: Supporting some version of “Medicare for All” has become a litmus test for a lot of Democratic primaries in 2018, and will surely be one in 2020.
What they’re saying: Tim Higginbotham and Chris Middleman, organizers with the Democratic Socialists of America’s Medicare for All campaign, pushed back against the squishier definitions of the term in a Vox op-ed on Friday.
The other side: Try writing, for example, a health policy newsletter that treats “Medicare for All” and “single-payer” as synonyms, and you’ll hear from the Democrats who support a less sweeping program, like an optional Medicare buy-in.
My thought bubble: Hardly anyone is actually talking about a literal expansion of the existing Medicare program, whether voluntary or compulsory.
Illustration: Sarah Grillo/Axios
The multi-hundred-billion-dollar retail prescription drugs market is the new battleground for Big Tech — in both the U.S. and China, my colleague Erica Pandey reports.
The bottom line: "There's just too much money to be made," says Sophie Cairns, a pharmaceutical analyst at IHS Markit, speaking of China's massive population and a growing demand for drugs that is forecast to surpass the U.S.
Dust off your abacus, because second-quarter health care earnings roll out this week, beginning with UnitedHealth Group and Johnson & Johnson on Tuesday. (Walgreens, operating on an oddball fiscal year, already posted its financial metrics.) Axios' Bob Herman has you covered with his updated health care earnings spreadsheet.
What to expect: Industry surveys indicate people are not being hospitalized or going to their doctor as often as the past, which means the big health insurance companies likely will continue to post huge cash flows.
America's Health Insurance Plans, the insurance industry's leading trade group, is announcing four new members today:
What we're watching this week: Senate health committee continues its series of hearings on health care costs Tuesday.
Energy and Commerce hearing Thursday on mental health and the 21st Century Cures Act.
What'd I miss? Let me know: email@example.com.